The announcement period of the 2021 annual report is approaching, and the performance of these pharmaceutical companies is expected to increase!

Up to now, more than 120 listed companies in Shanghai and Shenzhen have successively disclosed their 2021 annual report forecasts.
Most of them are pre-excited, and pre-excited companies are mainly concentrated in the two major industries of medicine, biology and chemical industry.
The number of companies is 12
.
In the pharmaceutical industry, there are at least five drug companies before the net profit growth habitat, including Westlands shares, the extension of An Bikang, Cape biological, Toho biological, Jolly Pharmaceutical and so on
.
Among them, Hualan Co.
, Ltd.
and Kaipu Biological are expected to increase their net profit by more than 100%
.
Specifically, Hualan expects that from January to December 2021, the net profit attributable to the owners of the parent company will be approximately 196 million yuan to 266 million yuan, a year-on-year increase of approximately 141.
64% to 226.
92%
.
The main business of the pharmaceutical company is the R&D, production and sales of packaging materials for direct contact injection drugs
.
Kaipu Biological expects that the net profit attributable to shareholders of listed companies in 2021 will be 800 million to 860 million yuan, a year-on-year increase of 120.
59% to 137.
14%
.
The company stated that during the reporting period, the company continued to promote the integrated business model of "nucleic acid testing products + medical testing services", and continued to implement the "nucleic acid 99 strategy" and the "Cape B53 nucleic acid remote strategic service plan".
The company's third-party medical experiment The office has actively participated in the prevention and control of the epidemic, and its business has achieved rapid development
.
Yan'an Bikang expects to achieve operating income of more than 9.
1 billion yuan in 2021, an increase of more than 11.
49% year-on-year; net profit of 950 million to 1 billion yuan
.
The company explained that during the reporting period, the operating income of environmentally friendly smart coke oven machinery products and calcium carbide furnace products increased significantly year-on-year, driving the company's overall profit to rise
.
It is reported that Yan’an Bikang’s main business is the research and development, production and sales of pharmaceutical intermediates, pesticide intermediates, and new energy and new materials
.
Dongbao Biotechnology expects to achieve a net profit of 30 million to 40 million yuan attributable to shareholders of the listed company in 2021, an increase of 62.
60% to 116.
80% compared to the previous year’s profit of 18.
453 million yuan.

.
As for the reasons for the anticipated performance increase, Dongbao Bio said that in 2021, the company's gelatin series product business will develop steadily, market demand will be good, sales volume and sales revenue will achieve further growth compared with the same period of the previous year, and sales profit will increase accordingly
.
Zuoli Pharmaceutical expects that the net profit attributable to shareholders of listed companies in 2021 will be 170 million yuan to 187 million yuan, an increase of 91.
44% to 110.
58% over the same period of the previous year
.
The company stated that during the reporting period, based on the advantages of the three core products of Wuling Capsules, Bailing Tablets, and Lingze Tablets in the National Essential Drug List, it adhered to the marketing strategy of “stabilizing self-operation, strong investment promotion, cloth retail, and full modules”, and continued Increase market investment and development coverage of terminal medical institutions
.
It is worth mentioning that according to the 2021 annual report appointment disclosure schedule announced by the exchange, the Chinese patent medicine manufacturer Wohua Pharmaceutical will become the first pharmaceutical company to disclose the 2021 annual report before the Lunar New Year
.
Affected by this news, Wohua Pharmaceutical hit its daily limit on January 4, and the stock has its daily limit once in the past year
.
Financial data shows that Wohua Pharmaceutical's 2020 revenue will exceed 1 billion yuan, and its net profit will exceed 100 million yuan.
The third quarter report of 2021 shows that the company achieved 711 million yuan in main operating income and 137 million yuan in net profit attributable to the parent in the first three quarters
.
Regarding the performance of the pharmaceutical and biological industry, some securities institutions believe that medicine is a rigid demand.
Under the upgrade of healthy consumption, the industry has long-term growth momentum.
At the same time, as the satisfaction and penetration rate of pharmaceutical demand increases, China's pharmaceutical industry will accelerate its growth.
With a long logical cycle and strong enough certainty, the future allocation of funds for consumer medicine will strengthen the allocation of medicine from the medium and long-term dimensions, which will lead to an increase in the overall level of medicine
.
It is worth optimizing in the long run .